Abstract

Apolipoprotein A-IV (apoA-IV) is a lipid binding protein expressed in mammalian intestine, as well as rodent liver. While previous in vitro studies demonstrated that apoA-IV promotes cellular triglyceride (TG) secretion by modulating apoB secretory trafficking and lipoprotein size, evidence that apoA-IV affects TG secretion in vivo is lacking. To explore the possible role of apoA-IV in controlling hepatic VLDL-mediated lipid efflux we assessed whether apoA-IV is regulated by liver lipid accumulation and if its deficiency or overexpression affects hepatic TG secretion. Under conditions of high fat diet-induced hepatic steatosis and steatosis caused by transgenic overexpression of SREBP-1a (SREBP-1aTg), a ~40-fold induction of hepatic apoA-IV mRNA and protein was observed. In both systems there was a linear correlation between hepatic TG content and apoA-IV mRNA abundance (r2 = 0.8965). To establish whether the induction of apoA-IV impacted TG secretion, SREBP-1aTg mice were crossed with apoA-IV knock out mice (A4-KO). Based on the Triton block method, SREBP1aTg/A4-KO mice demonstrated a 24% reduction in hepatic TG secretion rate, relative to SREBP1aTg controls. The basis for the decrease in TG secretion was not due to decreased particle number, as apoB production was unaffected; however, negative stain electron microscopy revealed a 33% decrease in the abundance of large diameter (>120 nm) VLDL particles. To explore the impact of human apoA-IV overexpression, a recombinant apoA-IV adenovirus (AdA4) was developed. Mice infected with AdA4 demonstrated abundant hepatic expression of human apoA-IV, and a 50% increase in hepatic TG secretion rate, relative to the LacZ control. In addition, after only three days of expression AdA4 reduced liver TG content by 40%. Although again, apoA-IV expression did not impact apoB secretion, negative stain electron microscopy revealed a 1.8-fold increase in the abundance of large diameter VLDL particles. In conclusion, we demonstrate that in steatotic mice, hepatic apoA-IV expression increases TG secretion by promoting lipoprotein particle expansion, thereby dramatically reducing hepatic lipid burden without increasing atherogenic lipoprotein particle number.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call